Ranked #7,388 of 8,699 institutional investors
Exome Asset Management LLC
New York, NY
$136M
US stock portfolio at live prices · today −$1.2M (−0.87%)
Live prices, last trade 9:41 AM ET
- Value at quarter end (Q3 2026)
- $153M
- Change from Q2 2026
- −$9.1M (−5.60%)
- Positions
- 51 · 9 new, 4 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$4.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesTGTX 8.97%GH 7.07%PRAX 6.70%LLY 5.51%ABVX 5.30%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| TGTX TG Therapeutics, Inc. | 187,671 | $12.2M | 8.97% | Added +14% |
| GH Guardant Health, Inc. | 67,500 | $9.6M | 7.07% | Unchanged |
| PRAX Praxis Precision Medicines, Inc. | 29,681 | $9.1M | 6.70% | Added +9% |
| LLY Eli Lilly and Company | 5,492 | $7.5M | 5.51% | Unchanged |
| ABVX ABIVAX Société Anonyme | 90,919 | $7.2M | 5.30% | Added +94% |
| COGT Cogent Biosciences, Inc. | 210,523 | $5.7M | 4.22% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 100,203 | $4.7M | 3.43% | Unchanged |
| VERA Vera Therapeutics, Inc. | 159,556 | $4.3M | 3.13% | Added +64% |
| NTRA Natera, Inc. | 13,800 | $3.9M | 2.88% | Unchanged |
| VKTX Viking Therapeutics, Inc. | 147,497 | $3.8M | 2.81% | Added +208% |
| RYTM Rhythm Pharmaceuticals, Inc. | 32,209 | $3.7M | 2.74% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 114,692 | $3.7M | 2.69% | Unchanged |
| LQDA Liquidia Corporation | 59,155 | $3.3M | 2.45% | Added +51% |
| CYTK Cytokinetics, Incorporated | 60,056 | $3.1M | 2.30% | Unchanged |
| IONS Ionis Pharmaceuticals, Inc. | 107,034 | $3.0M | 2.17% | Added +21% |
| VSTM Verastem, Inc. | 429,041 | $2.9M | 2.11% | Unchanged |
| CAI Caris Life Sciences, Inc. | 146,093 | $2.6M | 1.94% | Added +87% |
| GKOS Glaukos Corporation | 10,862 | $2.5M | 1.88% | Reduced −45% |
| NKTR Nektar Therapeutics | 73,708 | $2.4M | 1.74% | Added +229% |
| UTHR United Therapeutics Corporation | 4,109 | $2.3M | 1.70% | Reduced −24% |
| BSX Boston Scientific Corporation | 48,347 | $2.1M | 1.53% | Unchanged |
| PEN Penumbra, Inc. | 6,300 | $2.0M | 1.48% | Unchanged |
| ISRG Intuitive Surgical, Inc. | 4,908 | $2.0M | 1.48% | Unchanged |
| UNH UnitedHealth Group Incorporated | 5,697 | $1.9M | 1.43% | Reduced −41% |
| MLTX MoonLake Immunotherapeutics | 166,493 | $1.8M | 1.34% | Unchanged |
| MRK Merck & Co., Inc. | 12,358 | $1.7M | 1.23% | New |
| BBIO BridgeBio Pharma, Inc. | 21,209 | $1.6M | 1.21% | Added +16% |
| TXG 10x Genomics, Inc. | 30,074 | $1.6M | 1.19% | Reduced −71% |
| OCUL Ocular Therapeutix, Inc. | 272,046 | $1.6M | 1.17% | Added +50% |
| CLDX Celldex Therapeutics, Inc. | 56,269 | $1.5M | 1.13% | New |
| ARWR Arrowhead Pharmaceuticals, Inc. | 32,214 | $1.4M | 1.04% | Unchanged |
| REPL Replimune Group, Inc. | 68,488 | $1.3M | 0.96% | Added +70% |
| GLUE Monte Rosa Therapeutics, Inc. | 137,015 | $1.2M | 0.90% | Unchanged |
| ALMS Alumis Inc. | 282,253 | $1.2M | 0.89% | Added +38% |
| CMPS COMPASS Pathways plc | 153,087 | $1.2M | 0.88% | New |
| PVLA Palvella Therapeutics, Inc. | 7,809 | $1.1M | 0.84% | New |
| CTMX CytomX Therapeutics, Inc. | 460,067 | $948K | 0.70% | Unchanged |
| ZBIO Zenas BioPharma, Inc. | 34,341 | $863K | 0.64% | Reduced −35% |
| BLLN BillionToOne, Inc. | 8,983 | $805K | 0.59% | New |
| CLPT ClearPoint Neuro, Inc. | 110,174 | $803K | 0.59% | Added +32% |
| RAPP Rapport Therapeutics, Inc. | 29,381 | $695K | 0.51% | New |
| CLYM Climb Bio Inc | 71,215 | $645K | 0.47% | New |
| EQ Equillium, Inc. | 552,956 | $622K | 0.46% | Unchanged |
| QTTB Q32 Bio Inc. | 62,589 | $520K | 0.38% | New |
| NBP NovaBridge Biosciences | 576,960 | $502K | 0.37% | Unchanged |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 190,714 | $456K | 0.34% | Added +3% |
| CAPR Capricor Therapeutics, Inc. | 51,531 | $398K | 0.29% | New |
| CMPX Compass Therapeutics, Inc. | 511,084 | $347K | 0.26% | Added +85% |
| DRUG Bright Minds Biosciences Inc. | 14,715 | $298K | 0.22% | Added +46% |
| ABUS Arbutus Biopharma Corporation | 50,166 | $203K | 0.15% | Unchanged |
| ADAG Adagene Inc. | 52,543 | $104K | <0.1% | Reduced −89% |